Τίτλος:
Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Asthma is a chronic inflammatory disease of the airways that causes recurring episodes of wheezing, breathlessness, chest tightness and coughing. Inhaled drugs on a daily basis are the cornerstone of asthma treatment, therefore, patient adherence is very important. Methods: We performed a multicenter, open, non-interventional, observational, prospective study of 716 adult patients diagnosed with asthma receiving FDC (Fixed-dose combination) budesonide/formoterol via the Elpenhaler device. We assessed the adherence to treatment at 3 and 6 months (based on the MMAS-8: 8-item Morisky Medication Adherence Scale), the quality of life and change in forced expiratory volume in 1 s (FEV1) from baseline to follow-up. Results: Approximately 80% of the patients showed medium to high adherence throughout the study. The mean (SD) MMAS-8 score at 6 months was 6.85 (1.54) and we observed a statistically significant shift of patients from the low adherence group to the high adherence group at 6 months. Moreover, after 6 months of treatment with FDC budesonide/formoterol, we observed an increase in the patients’ quality of life that as expressed by a change 2.01 (95%CI 1.93–2.10) units in Mini AQLQ (p < 0.0001) that was more pronounced in the high adherence group. The same trend was also observed in terms of spirometry (mean FEV1 2.58 L (0.85) at the end of the study, increased by 220 mL from baseline) with a higher improvement in the medium and high adherence groups. Conclusions: Treatment with FDC of budesonide/formoterol via the Elpenhaler device was associated with improvement in asthma-related quality of life and lung function over 6 months that were more prominent in patients with higher adherence. Trial registration: 2017-HAL-EL-74 (ClinicalTrials.gov Identifier: NCT03300076). © 2022, The Author(s).
Συγγραφείς:
Exarchos, K.P.
Rovina, N.
Krommidas, G.
Latsios, D.
Gogali, A.
Kostikas, K.
Περιοδικό:
BMC Pulmonary Medicine
Εκδότης:
BioMed Central Ltd.
Λέξεις-κλειδιά:
budesonide plus formoterol; bronchodilating agent; budesonide; budesonide plus formoterol; ethanolamine derivative; formoterol fumarate, adult; aged; Article; asthma; clinical assessment; clinical feature; clinical practice; controlled study; disease severity; drug safety; drug withdrawal; female; follow up; forced expiratory volume; human; lung function; major clinical study; male; medication compliance; Morisky Medication Adherence Scale; multicenter study; observational study; patient compliance; prospective study; quality of life; spirometry; tachycardia; treatment duration; asthma; clinical trial; drug combination; treatment outcome, Adult; Asthma; Bronchodilator Agents; Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Drug Combinations; Ethanolamines; Formoterol Fumarate; Humans; Prospective Studies; Quality of Life; Treatment Outcome
DOI:
10.1186/s12890-022-02049-0
